Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Qualit-E-SpeakPharma-Insert
    X

    Find drug development pipeline and deal Updates information

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Open Orphan

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              Open Orphan’s Cathal Friel on firm’s “milestone” human coronavirus challenge study (ORPH)

              Contact the Supplier

              Lead Product(s): OC43 vaccine

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 09, 2020

              Details:

              For this human challenge study model, the common coronavirus strains such as OC43 and 229E, will provide an effective tool to obtain fast proof-of-concept data against this family of viruses.

              GlaxoSmithKline plc

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus

              Contact the Supplier

              Lead Product(s): 2019-nCoV vaccine

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: CEPI

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 03, 2020

              Details:

              GSK to make adjuvant technology available to support rapid development of candidate vaccines.

              PharmaCompass__DigitalAd